close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Redhill Biopharma Ltd. - American Depositary Shares (NQ:RDHL)

1.500 -0.070 (-4.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Redhill Biopharma Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead
Via Stocktwits
Wondering what's happening in today's pre-market session?
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Is RedHill Biopharma (RDHL) Stock Up 75% Today?
One of today's biggest market movers in the biotech space is RedHill Biuopharma, with RDHL stock up more than 75% on big news. 
Via InvestorPlace
Get insights into the top gainers and losers of Monday's after-hours session.
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
On Thursday, there are stocks with unusual volume. Let's take a look.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
Which stocks are moving after the closing bell on Wednesday?
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance
New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance 
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit
Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit 
Via News Direct
Topics Lawsuit
RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment
RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment 
Via News Direct
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results 
Via News Direct
Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes
RedHill Biopharma released study results showing opaganib's potential in treating Type 2 diabetes and obesity. The drug's ability to target sphingolipid metabolism could help prevent weight gain and... 
Via Benzinga
Crude Oil Moves Lower; Moderna Shares Plunge
 
Via Benzinga
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
 
Via Benzinga
Topics Stocks
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today